Ultrasound-guided Percutaneous Electrical Stimulation for Gluteus Muscle Dysfunction After Low Back Pain Episode
Launched by MARC BADIA · Mar 6, 2025
Trial Information
Current as of July 10, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new treatment called ultrasound-guided percutaneous neuromodulation (US-guided PNM) for people who have experienced low back pain and are dealing with issues related to their gluteus muscles (the large muscles in your buttocks). The researchers believe that using electrical stimulation at specific frequencies (between 20Hz and 100Hz) might help improve muscle strength and control better than the current standard frequency of 10Hz.
To participate in this trial, you need to be at least 18 years old and have a history of low back pain, but you shouldn’t be experiencing any acute pain during the study. You should also have some measurable weakness or dysfunction in your gluteus muscles. However, if you are pregnant, have certain heart conditions, or are currently dealing with active low back pain, you won’t be eligible to join. If you do participate, you can expect to undergo a series of electrical stimulations aimed at improving your muscle function, and you'll be closely monitored throughout the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients over 18 years of age
- • Healthy patients at the time of inclusion selection.
- • Patients with a history of low back pain, without acute episodes at the time of the study.
- • Patients who show an alteration in the function of the gluteus maximus and gluteus medius by EMG.
- • Patients who show a decrease in the strength of the gluteus maximus and gluteus medius by dynamometry.
- • Patients who have signed the information and consent document for participation.
- Exclusion Criteria:
- • Patients with belenophobia.
- • Pregnant patients.
- • Patients with cardiac pathologies or with pacemakers that do not allow electrical stimulation.
- • Patients with low back pain in the acute phase.
- • Patients with chronic low back pain.
- • Patients with skin or immune disorders with contraindications for the application of invasive techniques.
- • Patients who refuse to sign the informed consent or to participate in the study.
- • Individuals who are planning a change in their lifestyle that involves a change in relation to physical activity or training.
About Marc Badia
Marc Badia is a dedicated clinical trial sponsor specializing in the design, management, and execution of innovative research initiatives across various therapeutic areas. With a commitment to advancing medical knowledge and improving patient outcomes, Marc Badia leverages a robust network of industry partnerships and a wealth of expertise in regulatory compliance and trial methodology. The organization prioritizes ethical standards and patient safety while fostering collaboration among stakeholders, including healthcare professionals, researchers, and regulatory bodies. Through a rigorous approach to clinical development, Marc Badia strives to bring novel therapies to market efficiently and effectively.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sabadell, Barcelona, Spain
Patients applied
Trial Officials
Marc Badia Rosells, Physiotherapist
Principal Investigator
Universidad de Zaragoza
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported